OSI Pharmaceuticals Inc. and partners Genentech Inc. and Roche Holdings Inc. filed the first sections of a rolling new drug application for the cancer candidate Tarceva, an endothelial growth factor receptor inhibitor. (BioWorld Today)
OSI Pharmaceuticals Inc. and partners Genentech Inc. and Roche Holdings Inc. filed the first sections of a rolling new drug application for the cancer candidate Tarceva, an endothelial growth factor receptor inhibitor. (BioWorld Today)
